[Septic shock].
The problem of sepsis and septic shock (SSH) is known to be very actual due to peak-shaped growth of the number of such patients and unsatisfactory results of treatment. The occurrence of SSH is different--from 10% in the structure of infectious complications after polytrauma to 50% in patients with gram-negative sepsis in patients with burn disease. An analysis of treatment of 165 patients with SSH developed against the background of peritonitis has revealed high level of lethality (64%). In the pathogenesis of SSH an important role is played by immune disorders resulting in the development of generalized inflammation and polyorganic insufficiency. Treatment of patients with SSH must be necessarily supplemented with immuno-correcting techniques: use of medicines of nonspecific anti-cytokine action (pentoxyphillin) and regulators of the immune response (ronkoleukin, blood perfusion through the donor porcine spleen). The timely performed immunomodulating therapy allowed lethality of patients with SSH to be reduced to 32%.
Grinev
M V
MV
Bagnenko
S F
SF
Kulibaba
D M
DM
Gromov
M I
MI
D000007:Abdominal Injuries / Q000150:complications / Q000628:therapy; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D010538:Peritonitis / Q000150:complications / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012772:Shock, Septic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D007376:Interleukin-2; D011994:Recombinant Proteins; D010431:Pentoxifylline